METHODS OF GENERATING HUMAN INNER EAR SENSORY EPITHELIA AND SENSORY NEURONS
Provided herein are methods for directing differentiation of human pluripotent stem cells into inner ear sensory epithelia and sensory neurons. More particularly, provided herein are methods for obtaining three-dimensional cultures comprising human pluripotent stem cell-derived pre-otic epithelium, otic vesicles, and inner ear sensory epithelia containing hair cells, sensory neurons, and supporting cells.
Latest Indiana University Research and Technology Corporation Patents:
- Systems and methods for accurate measurement of proprioception
- Ferrochelatase inhibitors and methods of use
- Systems and methods for localized surface plasmon resonance biosensing
- MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS
- Survivin-targeting anti-tumor agents and uses thereof
This application claims the benefit of U.S. Provisional Application No. 62/244,568, filed Oct. 21, 2015, which is incorporated herein by reference as if set forth in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH ORDEVELOPMENT
This invention was made with government support under DC015624, DC012617, and DC013294 awarded by the National Institutes of Health. The government has certain rights in the invention.
FIELD OF THE INVENTIONProvided herein are methods for directing differentiation of human pluripotent stem cells into inner ear sensory epithelia and sensory neurons. More particularly, provided herein are methods for obtaining three-dimensional cultures comprising human pluripotent stem cell-derived pre-otic epithelium, otic vesicles, and inner ear sensory epithelia containing hair cells and supporting cells as well as sensory neurons innervating the sensory epithelia.
BACKGROUND OF THE INVENTIONNearly half a billion people have hearing loss world-wide, yet there are no pharmacological, genetic, or cell therapies that can treat hearing loss. This method could be used to generate human inner ear stem cells, supporting cells, hair cells and neurons for cell therapies or for use in drug discovery.
Accordingly, there remains a need in the art, for efficient, reproducible, and xenogeneic material-free methods for differentiating human pluripotent stem cells into inner ear sensory tissue suitable for clinical cell therapies.
SUMMARY OF THE INVENTIONIn a first aspect, provided herein is a method of obtaining human pre-otic epithelial cells. As described herein, the method comprises (a) culturing human pluripotent stem cell aggregates in a culture medium comprising a Bone Morphogenetic Protein (BMP) and an inhibitor of Transforming Growth Factor Beta (TGFβ) signaling for about eight to about 10 days; (b) further culturing the cultured aggregates of (a) in the presence of a Fibroblast Growth Factor (FGF) and an inhibitor of BMP signaling for about 4 days; and (b) contacting the further cultured aggregates of (b) to a Wnt agonist for about 4 days; whereby cells within the contacted aggregates differentiate into pre-otic epithelial cells. The FGF can be FGF-2. The BMP can be BMP2, BMP4, or BMP7. The inhibitor of BMP signaling can be LDN-193189. The inhibitor of TGFβ1-mediated signaling can be selected from the group consisting of SB431542 and A-83-01. The Wnt agonist can be an inhibitor of GSK3. The inhibitor of GSK3 is selected from the group consisting of CHIR99021, lithium chloride (LiCl), and 6-bromoindirubin-3′-oxime (BIO).
In another aspect, provided herein is a method of obtaining a three-dimensional composition comprising human inner ear sensory tissue, the method comprising the steps of (a) embedding human pre-otic epithelial cells obtained according to the method of claim 1 in a semi-solid culture medium comprising extracellular matrix protein; and (b) culturing the embedded pre-otic epithelial cells in the presence of a Wnt agonist for about 40 to about 60 days under conditions that promote self-assembly of embedded pre-otic epithelial cells into otic vesicles, whereby a three-dimensional composition comprising human inner ear sensory tissue is obtained. The Wnt agonist can be an inhibitor of GSK3, where the inhibitor of GSK3 is selected from the group consisting of CHIR99021, lithium chloride (LiCl), and 6-bromoindirubin-3′-oxime (BIO). The extracellular matrix can be a basement membrane extract (BME). The three-dimensional composition can comprise one or more mechanosensory cells. The three-dimensional composition can comprise one or more sensory neuron cells. The three-dimensional composition cam comprise one or more sensory neuron cells that form synaptic connections with mechanosensory cells.
These and other features, aspects, and advantages described herein will become better understood upon consideration of the following drawings, detailed description, and appended claims.
All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference in their entirety as if each individual publication, patent, and patent application was specifically and individually indicated to be incorporated by reference.
The present invention is based at least in part on the Inventors' discovery that human pluripotent stem cell-derived precursor cells cultured under conditions that are permissive towards differentiation and remodeling form highly uniform compositions of inner ear tissue that recapitulate the complexity and organization of human inner ear sensory epithelia and include functional hair cells. The Inventors discovered that it was possible to produce complex human tissues having the uniformity necessary for large-scale, quantitative in vitro modeling and screening applications.
Accordingly, the present invention relates to compositions including three-dimensional tissue constructs and cultures and methods of using such compositions as highly uniform models of human inner ear tissue and for screening drug candidates. In particular, provided herein are methods of efficiently and reproducibly producing and expanding complex, organized human inner ear sensory tissue suitable as a source of human hair cells for transplantation, as a model for understanding sensory deficits, and as a platform for screening drug candidates. An important advantage of the methods and systems provided herein is the ability to generate complex tissue constructs comprising multiple functional cell types from a single cell source. In addition, the methods and systems provided herein faithfully recapitulate in vivo development of complex, organized inner ear structural layers. The present invention provides a scalable and robust system for generating human inner ear sensory tissue as well as an important opportunity to study such tissues in an in vitro human model. In addition, methods of the present invention are useful for identifying materials and combinatorial strategies for human tissue engineering.
Methods
In exemplary embodiments, the methods provided herein comprise differentiating human pluripotent stem cells under conditions that promote differentiation of the pluripotent stem cells into inner ear sensory tissue. Generally, cells of inner ear sensory tissue are identified by their surface phenotype, by the ability to respond to growth factors, and being able to differentiate in vivo or in vitro into particular cell lineages.
In a first aspect, a method of obtaining human inner ear sensory tissue comprises aggregating human pluripotent stem cells into spheroids and culturing the spheroids for about three to four days in the presence of in a culture medium comprising factors that promote induction of non-neural epithelium (NNE). Such a culture medium comprises or consists essentially of the following chemically defined components: bone morphogenetic protein-4 (BMP4) and an inhibitor of transforming growth factor beta (TGFβ) signaling such as, for example, SB-431542 (“SB”), whereby at least a subset of the pluripotent stem cells are induced to differentiate to form a core of mesodermal cells within each aggregate. Preferably, aggregates comprising a core of mesodermal cells are cultured in the presence of BMP4 and an inhibitor of TGFβ signaling (e.g., SB) for about 8 days to about 10 days. SB-431542 is a specific inhibitor of the activin receptor-like kinase receptors ALKS, ALK4, and ALK7. Following the 8 to 10 day culture, cells of the mesodermal core migrate to the surface of the aggregates and produce a layer of non-neural epithelium within which inner ear organoids will develop. The non-neural epithelium that produces inner ear organoids, now lining the core of the aggregate, can eventually differentiate into epidermal tissue.
Referring to
Next, aggregates comprising pre-otic epithelium (i.e., OEPD) are embedded in a semi-solid culture medium such as, for example, a semi-solid composition of extracellular matrix proteins. The embedded aggregates are then cultured in the presence of a Wnt agonist until pre-otic epithelium self-assembles into organized otic vesicles. In some cases, aggregates comprising pre-otic epithelium are cultured in the presence of a Wnt agonist for about 10 days to about 14 days (e.g., about 10, 11, 12, 13, or 14 days).
Otic vesicle-laden aggregates are further cultured for at least about 40 days (e.g., about 40 days, about 45 days, about 50 days, about 60 days, about 65 days, about 70 days, about 75 days, or more), during which inner ear organoids comprising mechanosensory cells (e.g., hair cells) are obtained. Hair cells are specialized mechanosensory receptor cells of the vertebrate inner ear and lateral line organs that mediate hearing and balance.
To form aggregates, a confluent culture of pluripotent stem cells can be chemically, enzymatically or mechanically dissociated from a surface, such as Matrigel° into clumps, aggregates, or single cells. In exemplary embodiments, the dissociated cells (as clumps, aggregates, or single cells) are plated onto a surface in a protein-free basal medium such as Dulbecco's Modified Eagle's Medium (DMEM)/F12, mTeSR™ (StemCell Technologies; Vancouver, British Columbia, Canada), and TeSR™. The full constituents and methods of use of TeSR™ are described in Ludwig et al. See, e.g., Ludwig T, et al., “Feeder-independent culture of human embryonic stem cells,” Nat. Methods 3:637-646 (2006); and Ludwig T, et al., “Derivation of human embryonic stem cells in defined conditions,” Nat. Biotechnol. 24:185-187 (2006), each of which is incorporated herein by reference as if set forth in its entirety. Other DMEM formulations suitable for use herein include, e.g., X-Vivo (BioWhittaker, Walkersville, Md.) and StemPro® (Invitrogen; Carlsbad, Calif.).
In some cases, aggregates of pluripotent stem cells are cultured in the presence of a Rho kinase (ROCK) inhibitor. Kinase inhibitors, such as ROCK inhibitors, are known to protect single cells and small aggregates of cells. See, e.g., US Patent Application Publication No. 2008/0171385, incorporated herein by reference as if set forth in its entirety; and Watanabe K, et al., “A ROCK inhibitor permits survival of dissociated human embryonic stem cells,” Nat. Biotechnol. 25:681-686 (2007). ROCK inhibitors are shown below to significantly increase pluripotent cell survival on chemically defined surfaces. ROCK inhibitors suitable for use herein include, but are not limited to, (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine dihydrochloride (informal name: H-1152), 1-(5-isoquinolinesulfonyl)piperazine hydrochloride (informal name: HA-100), 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (informal name: H-7), 1-(5-isoquinolinesulfonyl)-3-methylpiperazine (informal name: iso H-7), N-2-(methylamino) ethyl-5-isoquinoline-sulfonamide dihydrochloride (informal name: H-8), N-(2-aminoethyl)-5-isoquinolinesulphonamide dihydrochloride (informal name: H-9), N-[2-p-bromo-cinnamylamino)ethyl]-5-isoquinolinesulfonamide dihydrochloride (informal name: H-89), N-(2-guanidinoethyl)-5-isoquinolinesulfonamide hydrochloride (informal name: HA-1004), 1-(5-isoquinolinesulfonyl) homopiperazine dihydrochloride (informal name: HA-1077), (S)-(+)-2-Methyl-4-glycyl-1-(4-methylisoquinolinyl-5-sulfonyl)homopiperazine dihydrochloride (informal name: glycyl H-1152) and (+)-(R)-trans-4-(1-aminoethyl)-N-(4-pyridyl)cyclohexanecarboxamide dihydrochloride (informal name: Y-27632). The kinase inhibitor can be provided at a concentration sufficiently high that the cells survive and remain attached to the surface. An inhibitor concentration between about 3 μM to about 10 μM can be suitable. At lower concentrations, or when no ROCK inhibitor is provided, undifferentiated cells typically detach, while differentiated cells remain attached to the defined surface.
FGF-2 is an agonist of FGF signaling, and FGF signaling can be antagonized using, for example, the small molecule inhibitor PD-173074. BMP4 is an agonist of BMP signaling, and BMP signaling can be antagonized using, for example, the small molecule inhibitor LDN-193189. TGFβ-1 and Activin A are agonists of TGFβ signaling, and TGFβ signaling can be antagonized using, for example, the small molecule inhibitor SB-431542. CHIR-99021 is an agonist of the Wnt/β-catenin signaling pathway, and Wnt/β-catenin signaling can be antagonized using, for example, the small molecule inhibitor XAV-939. Other Wnt agonists include inhibitors/antagonists of the molecule Glycogen Synthase Kinase 3 (GSK3).
In some cases, the semi-solid composition of extracellular matrix proteins is a commercially available product such as Geltrex® basement membrane matrix. Geltrex® basement membrane matrix is suitable for use with human pluripotent stem cell applications using StemPro® hESC SFM or Essential 8· media systems. In other cases, the semi-solid composition comprises two or more extra cellular matrix proteins such as, for example, laminin, entactin, vitronectin, fibronectin, a collagen, or combinations thereof.
Preferably, human pluripotent stem cells are cultured in a chemically-defined basal culture medium formulation comprising the defined components of culture medium “DF3 S” as set forth in Chen et al., Nature Methods 8:424-429 (2011), which is incorporated by reference herein as if set forth in its entirety. As used herein, the terms “E7 culture medium” and “E7” are used interchangeably and refer to a chemically defined culture medium comprising or consisting essentially of DF3S supplemented to further comprise insulin (20 μg/mL), transferrin (10.67 ng/mL) and human Fibroblast Growth Factor 2 (FGF2) (100 ng/mL). As used herein, the terms “E8 culture medium” and “E8” are used interchangeably and refer to a chemically defined culture medium comprising or consisting essentially of DF3S supplemented by the addition of insulin (20 μg/mL), transferrin (10.67 ng/mL), human FGF2 (100 ng/mL), and human TGFβ1 (Transforming Growth Factor Beta 1) (1.75 ng/mL).
Any appropriate method can be used to detect expression of biological markers characteristic of cell types described herein. For example, the presence or absence of one or more biological markers can be detected using, for example, RNA sequencing, immunohistochemistry, polymerase chain reaction, qRT-PCR, or other technique that detects or measures gene expression. In exemplary embodiments, a cell population obtained according to a method provided herein is evaluated for expression (or the absence thereof) of biological markers of pre-otic epithelial cells and otic placode such as Foxi1, Dlx genes, Pax8, Pax2, Sox3, Eya1, Gata3, Gbx2, and Sox9. Quantitative methods for evaluating expression of markers at the protein level in cell populations are also known in the art. For example, flow cytometry is used to determine the fraction of cells in a given cell population that express or do not express biological markers of interest. Differentiated cell identity is also associated with downregulation of pluripotency markers such as NANOG and OCT4 (relative to human ES cells or induced pluripotent stem cells).
As used herein, “pluripotent stem cells” appropriate for use according to a method of the invention are cells having the capacity to differentiate into cells of all three germ layers. Suitable pluripotent cells for use herein include human embryonic stem cells (hESCs) and human induced pluripotent stem (iPS) cells. As used herein, “embryonic stem cells” or “ESCs” mean a pluripotent cell or population of pluripotent cells derived from an inner cell mass of a blastocyst. See Thomson et al., Science 282:1145-1147 (1998). These cells express Oct-4, SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81, and appear as compact colonies having a high nucleus to cytoplasm ratio and prominent nucleolus. ESCs are commercially available from sources such as WiCell Research Institute (Madison, Wis.). As used herein, “induced pluripotent stem cells” or “iPS cells” mean a pluripotent cell or population of pluripotent cells that may vary with respect to their differentiated somatic cell of origin, that may vary with respect to a specific set of potency-determining factors and that may vary with respect to culture conditions used to isolate them, but nonetheless are substantially genetically identical to their respective differentiated somatic cell of origin and display characteristics similar to higher potency cells, such as ESCs, as described herein. See, e.g., Yu et al., Science 318:1917-1920 (2007).
Induced pluripotent stem cells exhibit morphological properties (e.g., round shape, large nucleoli and scant cytoplasm) and growth properties (e.g., doubling time of about seventeen to eighteen hours) akin to ESCs. In addition, iPS cells express pluripotent cell-specific markers (e.g., Oct-4, SSEA-3, SSEA-4, Tra-1-60 or Tra-1-81, but not SSEA-1). Induced pluripotent stem cells, however, are not immediately derived from embryos. As used herein, “not immediately derived from embryos” means that the starting cell type for producing iPS cells is a non-pluripotent cell, such as a multipotent cell or terminally differentiated cell, such as somatic cells obtained from a post-natal individual.
Human iPS cells can be used according to a method described herein to obtain primitive macrophages and microglial cells having the genetic complement of a particular human subject. For example, it may be advantageous to obtain inner ear sensory cells that exhibit one or more specific phenotypes associated with or resulting from a particular disease or disorder of the particular mammalian subject. In such cases, iPS cells are obtained by reprogramming a somatic cell of a particular human subject according to methods known in the art. See, for example, Yu et al., Science 324(5928):797-801 (2009); Chen et al., Nat. Methods 8(5):424-9 (2011); Ebert et al., Nature 457(7227):277-80 (2009); Howden et al., Proc. Natl. Acad. Sci. U. S. A. 108(16):6537-42 (2011). Induced pluripotent stem cell-derived inner ear sensory tissues can be used to screen drug candidates in tissue constructs that recapitulate inner ear sensory tissue in an individual having, for example, a particular disease. Subject-specific somatic cells for reprogramming into induced pluripotent stem cells can be obtained or isolated from a target tissue of interest by biopsy or other tissue sampling methods. In some cases, subject-specific cells are manipulated in vitro prior to use in a three-dimensional tissue construct of the invention. For example, subject-specific cells can be expanded, differentiated, genetically modified, contacted to polypeptides, nucleic acids, or other factors, cryo-preserved, or otherwise modified prior to introduction to a three-dimensional tissue construct.
Preferably, human pluripotent stem cells (e.g., human ESCs or iPS cells) are cultured in the absence of a feeder layer (e.g., a fibroblast layer), a conditioned medium, or a culture medium comprising poorly defined or undefined components. As used herein, the terms “chemically defined medium” and “chemically defined cultured medium” also refer to a culture medium containing formulations of fully disclosed or identifiable ingredients, the precise quantities of which are known or identifiable and can be controlled individually. As such, a culture medium is not chemically defined if (1) the chemical and structural identity of all medium ingredients is not known, (2) the medium contains unknown quantities of any ingredients, or (3) both. Standardizing culture conditions by using a chemically defined culture medium minimizes the potential for lot-to-lot or batch-to-batch variations in materials to which the cells are exposed during cell culture. Accordingly, the effects of various differentiation factors are more predictable when added to cells and tissues cultured under chemically defined conditions. As used herein, the term “serum-free” refers to cell culture materials that are free of serum obtained from animal (e.g., fetal bovine) blood. In general, culturing cells or tissues in the absence of animal-derived materials (i.e., under xenogen-free conditions) reduces or eliminates the potential for cross-species viral or prion transmission.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Although any methods and materials similar to or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described herein.
As used herein, “a medium consisting essentially of” means a medium that contains the specified ingredients and those that do not materially affect its basic characteristics.
As used herein, “effective amount” means an amount of an agent sufficient to evoke a specified cellular effect according to the present invention.
As used herein, “about” means within 5% of a stated concentration range, density, temperature, or time frame.
The invention will be more fully understood upon consideration of the following non-limiting Examples. It is specifically contemplated that the methods disclosed are suited for pluripotent stem cells generally. All papers and patents disclosed herein are hereby incorporated by reference as if set forth in their entirety.
EXAMPLES Example 1 Generation of Inner Ear Organoids with Functional Hair Cells from Human Pluripotent Stem CellsThe human inner ear contains approximately 20,000 sensory hair cells that detect sound and movement via mechanosensitive stereocilia bundles1. Genetic mutations or environmental insults, such as loud noises, can cause irreparable damage to these hair cells, leading to dizziness or hearing loss2,3. We previously demonstrated how to generate inner ear organoids from mouse pluripotent stem cells (PSCs) using timed manipulation of the FGF, TGFβ, BMP, and Wnt signaling pathways in a 3D culture system4-6. We have shown that mouse inner ear organoids contain sensory hair cells with similar structure and function to native vestibular hair cells in the mouse inner ear7. Moreover, our past findings bolstered a working model of otic induction signaling dynamics, wherein BMP signaling activation and TGFβ inhibition initially specifies non-neural ectoderm and subsequent BMP inhibition and FGF activation induces a pre-otic fate8,9. Despite several recent attempts, a developmentally faithful approach for deriving functional hair cells from human PSCs (hPSC) has yet to be describer10-15. Here, to generate human inner ear tissue from hPSCs, we first established a timeline of in vitro human inner ear organogenesis (
We first confirmed that dissociated human embryonic stem cells (hESCs; WA25 cell line, WiCell) aggregated well in E8 Medium containing a ROCK inhibitor, Y-27632, and displayed superior uniformity and cell-survival compared to cells aggregated in a chemically-defined differentiation medium (hereafter, CDM;
Following a 2-day incubation in E8 Medium, we transferred aggregates to CDM containing a low concentration of Matrigel and FGF-2 to stimulate epithelization and ectoderm differentiation on the aggregate surface. We previously showed that a combination of BMP4 and the TGFβ inhibitor SB-431542 (hereafter, “SB”) promoted non-neural induction from mouse PSCs (mPSCs)6. We found that combining 10 ng/ml BMP4 and 10 μM SB (dual SB/BMP4 treatment referred to as “SBB”) induces not only non-neural marker genes, such as TFAP2 and DLX3, but also the extraembryonic marker CDX2 (
Curious whether endogenous BMP activity is sufficient for non-neural specification, we performed a co-treatment with the BMP inhibitor, LDN-193189 (hereafter, LSB; dual LDN/SB treatment referred to as LSB). As previously shown in hESC monolayer cultures18, LSB treatment to WA25 aggregates up-regulated neuroectoderm markers, such as PAX6 and N-cadherin (NCAD), and abolished TFAP2 and ECAD expression, suggesting that endogenous BMP signals drive non-neural conversion (
Next, we attempted to convert the non-neural epithelium into otic placode epithelium prior to keratinocyte commitment. Human cranial placodes arise at approximately 18-24 dpc; thus, assuming hPSCs represent cells at ˜12 dpc, otic placodes would develop in our culture within the first 6-12 days of differentiation with proper signaling modulation (
To promote PAX2 expression and vesicle formation, we began testing various signaling modulators (
We cultured the aggregates in stationary droplets until day 18, then transferred them to a 24-well plate on an orbital shaker or a spinner flask for further self-organized maturation—both formats produced comparable results. At 20-30 days in culture, vesicles remained visible through the surface of 71.7±23.3% aggregates examined (n=37, 3 experiments;
After 40-60 days of incubation, vesicles with complex multi-chambered morphologies were visible through the aggregate surface (
To facilitate live-cell imaging and electrophysiological experiments, we engineered a novel hESC reporter cell line to endogenously label hair cells with enhanced green fluorescent protein (eGFP). We used the CRISPR/Cas9 system to insert a 2A-eGFP gene cassette at the stop codon of the ATOH1 gene, which is highly expressed during hair cell induction and early maturation (
Finally, we wondered whether the derived hair cells functioned similar to native mammalian hair cells. Using aggregates produced from ATOH1-2A-eGFP cells, we dissected and flat-mounted inner ear organoids between differentiation days 63-67. To our knowledge, these constitute the first recordings of human hair cells derived from hPSCs. The cells had large outwardly-rectifying currents, but no Na+ current (seen in developing rodent hair cells, but absent in most mature hair cells) was detected in our sample (
In conclusion, we have established a robust culture system for guiding the development of human inner ear organoids in culture (
Methods and Materials
hPSC culture: Human PSCs (WA25 hESCs, passage 22-50; mND2-0 iPSCs, passage 28-46) were cultured in Essential 8 (E8) Medium or Essential 8 Flex Medium (E8f) (Invitrogen) supplemented with 100 μg/ml Normocin (Invivogen) on recombinant human Vitronectin-N (Invitrogen)-coated 6-well plates according to an established protocol12,13. At 80% confluency or every 4-5 days, the cells were passaged at a split ratio of 1:10-1:20 using an EDTA solution. Both cell lines were acquired from the WiCell Research Institute and arrived with a statement of verification and authenticity. Additional validation and testing information can be found on the cell line webpages, available at wicell.org/home/stem-cell-lines/catalog-of-stem-cell-lines/wa25.cmsx and wicell.org/home/stem-cell-lines/catalog-of-stem-cell-lines/mirjt7i-mnd2-0.cmsx on the World Wide Web. Cell lines were determined to be mycoplasma contamination-free using the MycoAlert Mycoplasma Detection Kit (Lonza).
hPSC differentiation. To start differentiation, hPSC cells were dissociated with StemPro Accutase (Invitrogen) and distributed, 5,000 cells per well, onto 96-well V-bottom plates in E8 medium containing 20 μM Y-27632 (Stemgent) and Normocin. Following a 48 hour incubation, the aggregates were transferred to 96-well U-bottom plates in 100 μl of Chemically Defined Medium (CDM) containing 4 ng m1−1 FGF-2 (Peprotech), 10 μM SB-431542 (Stemgent), and, for some experiments, 2.5 ng ml−1 BMP4 (Stemgent), and 2% Growth Factor Reduced (GFR) Matrigel (Corning) to initiate non-neural induction—i.e. differentiation day 0. CDM contained a 50:50 mixture of F-12 Nutrient Mixture with GlutaMAX (Gibco) and Iscove's Modified Dulbecco's Medium with GlutaMAX (IMDM; Gibco) additionally supplemented with 0.5% Bovine Serum Albumin (BSA), 1× Chemically Defined Lipid Concentrate (Invitrogen), 7 μg ml−1 Insulin (Sigma), 15 μg ml−1 Transferrin (Sigma), 450 μM Mono-Thioglycerol, and Normocin (see Table 1 for a detailed formulation). After 4 days of incubation, 25 μl of CDM containing a 250 ng ml−1 FGF-2 (50 ng/ml final concentration) and 1 μM LDN-193189 (200 nM final concentration) was added to the pre-existing 100 μl of media in each well. After an additional 4 days (8 days total), 25 μl of CDM was added to the media. For some experiments, CDM containing a 18 μM CHIR99021 (3 μM final concentration; Stemgent) was added to the pre-existing 125 μl of media in each well—we determined that this treatment is optional for inner ear organoid production, but may improve induction of otic placode-like cells. On differentiation day 12, the aggregates were pooled together and washed with freshly prepared Organoid Maturation Medium (OMM) containing a 50:50 mixture of Advanced DMEM:F12 (Gibco) and Neurobasal Medium (Gibco) supplemented with 0.5× N2 Supplement (Gibco), 0.5× B27 without Vitamin A (Gibco), 1× GlutaMAX (Gibco), 0.1 mM B-Mercaptoethanol (Gibco), and Normocin (see Table 3 for a detailed formulation).
The formulation set forth in Table 3 provides for 50 mL of medium, which should be used for <2 weeks. OMNI is a custom-made hybrid of two media previously used to generate cerebral and gastric organoids6,7. B27 without Vitamin A was used to limit the influence of endogenously produced retinoic acid.
The aggregates were resuspended in ice cold undiluted GFR Matrigel and placed in approximately 25 μl droplets on the surface of a 100 mm bacterial culture plate. After at least 30 minutes of incubation at 37° C., the droplets were bathed in 10 ml of OMNI containing 3 μM CHIR99021. For non-droplet otic induction, the aggregates were washed and plated individually into each well of a 24-well low cell adhesion plate in OMNI containing 3μM CHIR and 1% GFR Matrigel. After 18 days of differentiation, the CHIR was removed from the medium by washing and the droplet aggregates were moved to a floating culture. Droplets were carefully dislodged using a wide-mouth 1000P tip and transferred to 75 ml of fresh OMNI in a 125 ml disposable spinner flask (Corning). Spinner flasks were maintained on an in-incubator stir plate (Thermo Scientific) at 65 RPM for up to 180 days of differentiation. For some experiments, the aggregates were maintained in individual wells of 24-well low-cell adhesion plates in 1 ml of OMM on an in-incubator orbital shaker (Thermo Scientific) for up to 140 days.
Choice of Media Components: We used two media components that may lead to variability in results due to lack of definition or poor compatibility with human cells: GFR Matrigel and BSA. GFR (Growth Factor Reduced) Matrigel contains, <0.1 pg ml−1 FGF-2, <0.5 ng ml−1 EGF, 5 ng ml−1 IGF-1, <5 pg ml−1 PDGF, <0.2 ng ml−1 NGF, and 1.7 ng ml−1 TGFβ. In particular, the TGFβ in GFR Matrigel may have impacted cell fate specification on day 12 or later because we did not include a TGFβ inhibitor in the media during that phase of culture. GFR Matrigel was chosen because it has been shown to be a reliable inducer of self-organizing epithelia from pluripotent stem cells in 3D culture26. GFR Matrigel is a more defined alternative to Matrigel, in which the concentration of growth factors, such as Egf, Igf1, Fgf2, and TGFβ, have been minimized to levels that should have a negligible effect on cell fate specification. In Other alternatives to Matrigel include, without limitation, synthetic hydrogels and recombinant protein-based matrices that support basement membrane formation and self-organization of differentiating PSCs into epithelia. For example, a purified Laminin/Entactin complex (Corning) may be a suitable, fully chemically defined alternative27. In the CDM, BSA was chosen as a cost-effective and easy to dissolve alternative to Human Serum Albumin and Polyvinyl Alcohol (PVA), respectively. PVA has been shown to be a suitable chemically defined substitute for BSA in CDM28.
Signaling molecules and recombinant proteins. The following small molecules and recombinant proteins were used: recombinant human BMP4 (2.5-10 ng ml−1; Stemgent), human FGF-2 (25 ng ml−1; Peprotech), SB-431542 (10 μM; Tocris Bioscience), CHIR99021 (3 μM; Stemgent), and LDN-193189 (200 nM; Stemgent).
Quantitative PCR. Analysis was performed as previously described on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems) or a Bio-Rad CFX96 quantitative PCR machine (Bio-Rad)6. Data were normalized to L27 expression (internal control) and the fold change was calculated relative to Ct values from d0 WA25 aggregates using the AACt method. Unless stated otherwise, data represent at least 3 separate biological samples from separate experiments. All indicators of statistical significance refer to comparisons between a given condition and the control group. Refer to Table 4 for primer details.
Immunohistochemistry. Aggregates were fixed with 4% paraformaldehyde for 20 min at room temperature or at 4° C. overnight. The fixed specimens were cryoprotected with a graded treatment of 15% and 30% sucrose and then embedded in tissue freezing medium. Frozen tissue blocks were sectioned into 12 μm cryosections on a Leica CM-1860 cryostat. For immunostaining, a 10% goat or horse serum in 0.1% Triton X-100 1× PBS solution was used for blocking, and a 3% goat or horse serum in 0.1% Triton X-100 1× PBS solution was used for primary/secondary antibody incubations. Alexa Fluor conjugated anti-mouse, rabbit, or goat IgG (Invitrogen) were used as secondary antibodies. Prolong Gold with DAPI (Thermo Scientific) was used to mount the samples and visualize cellular nuclei. For wholemount staining, a similar staining paradigm was used; however, the Triton X-100 concentration was increased to 0.5%, and the blocking and primary/secondary incubations were done at 37° C. on a rotating shaker for 24 hours and 48 hours, respectively. Following each incubation, the samples were subjected to three 1-hour washes in 1× PBS containing 0.5% Triton X-100 at 37° C. on a rotating shaker. Wholemount samples were mounted in ScaleA2 clearing solution for 1-2 days or ScaleSQ(5) clearing solution for 1-2 hours prior to imaging29. Microscopy was performed on a Lieca DMi8 inverted microscope, a Nikon TE2000 inverted microscope, or an Olympus FV1000-MPE Confocal/Multiphoton Microscope. 3D reconstruction was performed using the Imaris 8 software package (Bitplane) housed at the Indiana Center for Biological Microscopy. For segmentation analysis, 2A-eGFP cells were processed using the ‘Spots’ module in Imaris. Classification was based on estimated size, quality and signal intensity. Objects touching the border of the image were excluded. The following build parameters were used to identify 2A-eGFP+ cell bodies: estimated XY diameter=3.50 μm; estimated Z diameter=7.00 μm; ‘Quality’ above 20.0; ‘distance to image border XYZ’ above 0.001 μm; ‘intensity center Ch=1’ above 1,500. Movies were generated in Imaris from the raw image files and compiled in Adobe Premiere Pro to add titles and text. See Table 5 for a list of antibodies.
Electrophysiological recordings. Human organoids were shipped at day 62 in cold Hibernate A medium supplemented with 1× GlutaMax, 1× B27 Supplement, and Normocin. They were replaced back into OMM on day 63 in an incubator at 5% CO2 and 37° C. On recording days, organoids were dissected out using sharp tungsten needles (Fine Science Tools) and pinned to glass coverslips. The 2A-eGFP+ signal was used to find areas with hair cells and to target hair cells for recording. Whole-cell patch clamp was performed on the semi-intact tissue with 4-5 MΩ glass electrodes. Data were acquired using an Axopatch 200B amplifier (Molecular Devices), filtered at 5000 Hz, then digitized at 20 kHz through a Digidata 1322A converter. The recording pipette solution contained (in mM): 135 KC1, 5 HEPES, 5 EGTA, 2.5 MgCl2, 2.5 K2-ATP, 0.1 CaCl2, adjusted with KOH to pH 7.4, ˜285 mmol kg−1. The external solution contained: 137 NaCl, 5.8 KCl, 0.7 NaH2PO4, 10 HEPES, 1.3 CaCl2, 0.9 MgCl2, 5.6 Glucose, and was supplemented with vitamins and essential amino acids (Invitrogen, Carlsbad, Calif.), adjusted to pH 7.4 with NaOH, ˜310 mmol kg−1. Recordings were compensated 40% and cells were held at −66 mV for voltage clamp. Averages are reported±SEM.
Generation of ATOH1-2A-eGFP reporter cell line. gRNAs (5′-TCGGATGAGGCAAGTTAGGA-3′ (SEQ ID NO:17) and 5′-GTCACTGTAATGGGAATGGG-3′ (SEQ ID NO:18), offset=Obp) targeting the stop codon region of ATOH1 were cloned into pSpCas9n(BB) vectors which express Cas9n under the control of CBh promoter (Addgene #48873)30. To construct the donor vector, a 2A-eGFP-PGK-Puro cassette (Addgene #31938)17 flanked by two 1 kb homology arms PCR amplified from extracted WA25 hESC genomic DNA were cloned into a pUC19 backbone. The two gRNA vectors and the donor vector, as well as a vector expressing Cas9n under the control of CMV promoter (Addgene #41816)18 were transfected into WA25 hESCs with 4D Nucleofector (Lonza) using the P3 Primary Cell 4D-Nucleofector X kit and Program CB-150. After nucleofection, cells were plated in growth medium containing 1× RevitaCell (Thermo Fisher) for improved cell survival rate, and 1 μM of Scr7 (Xcessbio) for higher HDR efficiency31. 0.5 μg μl−1 puromycin selection was performed for 10 days starting from 48 h post-nucleofection. The PGK-Puro sub-cassette flanked by two LoxP sites was removed from the genome after puromycin selection by nucleofection of a Cre recombinase expressing vector (Addgene #13775). Clonal cell lines were established by low-density seeding (1-3 cells cm−2) of dissociated single hESCs followed by isolation of hESC colonies after 5-7 days of expansion. Genotypes of the clonal cell lines were analyzed by PCR amplification followed by gel electrophoresis, and by Sanger sequencing of total PCR amplicons or individual PCR amplicons cloned into TOPO vectors. Cell lines with bi-allelic 2A-eGFP integration were used for inner ear hair cell differentiation.
Statistical analysis. All statistics were performed using GraphPad Prism 7 software. A Shapiro-Wilk normality test was used prior to analysis to determine that the data had a normal distribution. Statistical significance was determined using a one-way analysis of variance (ANOVA) followed by a Dunnett's post-hoc test for multiple comparisons to a control group (e.g. vehicle treated). A Brown-Forsythe test was used to determine that the variation among sample groups was similar. No statistical test was used to predetermine sample size, the investigators were not blinded to the treatment groups, and the samples were not randomized.
Representative Data and Reproducibility. Unless stated otherwise, images are representative of specimens obtained from at least 3 separate experiments. For IHC analysis of aggregates between days 0-12, we typically sectioned 3-6 aggregates from each condition in each experiment. IHC analyses for later stages of the protocol were performed on at least 2 aggregates from each condition per experiment. The finalized culture method was successfully replicated 15 times by four independent investigators using the WA25 (wild-type or ATOH1-2A-eGFP) cell line. The method, with noted modifications, was replicated 3 times using the mND2-0 iPSC line. A replication was deemed successful by confirming pit/vesicle formation during days 12-18 and positively identifying inner ear organoids in at least one aggregate on days 50-100 of differentiation. Experiments were excluded from analysis if no pits were observed during days 12-18.
REFERENCES1. Géléoc, G. S. G. & Holt, J. R. Sound strategies for hearing restoration. Science 344, 1241062 (2014).
2. Müller, U. & Barr-Gillespie, P. G. New treatment options for hearing loss. Nat Rev Drug Discov 14, 346-365 (2015).
3. Sergeyenko, Y., Lall, K., Liberman, M. C. & Kujawa, S. G. Age-Related Cochlear Synaptopathy: An Early-Onset Contributor to Auditory Functional Decline. 33, 13686-13694 (2013).
4. DeJonge, R. E., Deig, C. R., Heller, S., Koehler, K. R. & Hashino, E. Modulation of Wnt signaling enhances inner ear organoid development in 3D culture. PLoS ONE
5. Koehler, K. R. & Hashino, E. 3D mouse embryonic stem cell culture for generating inner ear organoids. Nature Protocols 9, 1229-1244 (2014).
6. Koehler, K. R., Mikosz, A. M., Molosh, A. I., Patel, D. & Hashino, E. Generation of inner ear sensory epithelia from pluripotent stem cells in 3D culture. Nature 500, 217-221 (2013).
7. Liu, X.-P., Koehler, K. R., Mikosz, A. M., Hashino, E. & Holt, J. R. Functional development of mechanosensitive hair cells in stem cell-derived organoids parallels native vestibular hair cells. Nature Communications (2016).
8. Leung, A. W., Kent Morest, D. & Li, J. Y. H. Differential BMP signaling controls formation and differentiation of multipotent preplacodal ectoderm progenitors from human embryonic stem cells. Developmental biology 379, 208-220 (2013).
9. Kwon, H.-J., Bhat, N., Sweet, E. M., Cornell, R. A. & Riley, B. B. Identification of early requirements for preplacodal ectoderm and sensory organ development. PLoS genetics 6, e1001133 (2010).
10. Chen, J.-R. et al. Effects of genetic correction on the differentiation of hair cell-like cells from iPSCs with MYO15A mutation. Cell Death & Differentiation (2016). doi:10.1038/cdd.2016.16
11. Tang, Z.-H. et al. Genetic Correction of Induced Pluripotent Stem Cells From a Deaf
Patient With MYO7A Mutation Results in Morphologic and Functional Recovery of the Derived Hair Cell-Like Cells. Stem Cells Transl Med 5, 561-571 (2016).
12. Ohnishi, H. et al. Limited hair cell induction from human induced pluripotent stem cells using a simple stepwise method. Neuroscience Letters 599, 49-54 (2015).
13. Ealy, M., Ellwanger, D. C., Kosaric, N., Stapper, A. P. & Heller, S. Single-cell analysis delineates a trajectory toward the human early otic lineage. PNAS 201605537 (2016). doi:10.1073/pnas.1605537113
14. Ronaghi, M. et al. Inner Ear Hair Cell-Like Cells from Human Embryonic Stem Cells. Stem Cells and Development 23, 1275-1284 (2014).
15. Chen, W. et al. Restoration of auditory evoked responses by human ES-cell-derived otic progenitors. Nature 490, 278-282 (2012).
16. Lim, R. & Brichta, A. M. Anatomical and physiological development of the human inner ear. Hearing research (2016). doi:10.1016/j.heares.2016.02.004
17. Roberts, R. M. et al. Differentiation of trophoblast cells from human embryonic stem cells: to be or not to be? Reproduction 147, D1-12 (2014).
18. Chambers, S. M. et al. Combined small-molecule inhibition accelerates developmental timing and converts human pluripotent stem cells into nociceptors. Nature Biotechnology 30, 715-720 (2012).
19. Ladher, R. K., O'Neill, P. & Begbie, J. From shared lineage to distinct functions: the development of the inner ear and epibranchial placodes. Development 137, 1777-1785 (2010).
20. Groves, A. K. & Fekete, D. M. Shaping sound in space: the regulation of inner ear patterning. Development 139, 245-257 (2012).
21. Ohyama, T., Mohamed, O. A., Taketo, M. M., Dufort, D. & Groves, A. K. Wnt signals mediate a fate decision between otic placode and epidermis. Development 133, 865-875 (2006).
22. Hartman, B. H., Durruthy-Durruthy, R., Laske, R. D., Losorelli, S. & Heller, S.
Identification and characterization of mouse otic sensory lineage genes. Frontiers in cellular neuroscience 9, 79 (2015).
23. Burns, J. C., Kelly, M. C., Hoa, M., Morell, R. J. & Kelley, M. W. Single-cell RNA-Seq resolves cellular complexity in sensory organs from the neonatal inner ear. Nature Communications 6, 8557 (2015).
24. Géléoc, G. S. G., Risner, J. R. & Holt, J. R. Developmental acquisition of voltage-dependent conductances and sensory signaling in hair cells of the embryonic mouse inner ear. The Journal of neuroscience: the official journal of the Society for Neuroscience 24, 11148-11159 (2004).
25. Liu, X.-P., Koehler, K. R., Mikosz, A. M., Hashino, E. & Holt, J. R. Functional development of mechanosensitive hair cells in stem cell-derived organoids parallels native vestibular hair cells. Nature Communications 7,11508 (2016).
26. Huch, M. & Koo, B.-K. Modeling mouse and human development using organoid cultures. Development 142, 3113-3125 (2015).
27. Nasu, M. et al. Robust Formation and Maintenance of Continuous Stratified Cortical
Neuroepithelium by Laminin-Containing Matrix in Mouse ES Cell Culture. PLoS ONE 7, e53024 (2012).
28. Hannan, N. R. F., Segeritz, C.-P., Touboul, T. & Vallier, L. Production of hepatocyte-like cells from human pluripotent stem cells. Nature Protocols 8, 430-437 (2013).
29. Hama, H. et al. ScaleS: an optical clearing palette for biological imaging. Nature Neuroscience 18, 1518-1529 (2015).
30. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8, 2281-2308 (2013).
31. Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nature Biotechnology 33, 538-542 (2015).
Example 2 Modeling Otic NeurogenesisIn day-12 aggregates, we observed patches of PAX8+ PAX2+ epithelia reminiscent of otic placodes; therefore, we assayed for culture conditions promoting otic vesicle formation. Under control conditions (DMSO), we did not observe vesicle formation (data not shown). Since otic induction is dependent on Wnt signaling, we treated 12-day aggregates with a potent GSK3β inhibitor and known Wnt signaling agonist27, CHIR99021 (CHIR), between days 12-18. Under these conditions, PAX8+ PAX2+ SOX10+ vesicles evaginate from the outer epithelium (˜10-30 vesicles per aggregate; see
After 12 days of differentiation, otic induced aggregates were plated on bacterial dishes in Matrigel droplets in medium containing 3 μM CHIR. See
As further evidence of inner ear organogenesis in our culture system, the hair cells displayed CTBP2+ puncta by day 60-70 of culture, indicating putative ribbon synapse-like structures (
This example describes a protocol for inducing formation of non-neural ectoderm and inner ear sensory tissue from human pluripotent stem cells. As described in greater detail in the following paragraphs, pluripotent stem cells aggregates were cultured in a medium containing Matrigel, which is rich in basement membrane proteins, to induce ectoderm development and production of ectoderm epithelium on the aggregate surface. We then used a combined treatment of bone morphogenetic protein-4 (BMP4) and a transforming growth factor beta (TGFβ) inhibitor such as the small molecule SB-431542 (“SB”) to promote non-neural differentiation in the epithelium. To further initiate inner ear induction, BMP signaling was inhibited and fibroblast growth factor (FGF) signaling was activated using recombinant FGF-2 approximately 24 hours after the initial BMP4 and SB treatment. Remarkably, the combined treatment protocol initiated self-organization of otic vesicles that later developed into inner ear organoids containing functional vestibular sensory epithelia.
Methods
ES cell culture in E8 medium on Vitronectin-coated plates (steps 1-7). We maintain our hPS cells in E8 Medium under feeder-free conditions and use EDTA for passaging (see previous protocol by Beers et al.)1 We prefer this method of hPS cell maintenance because, in our hands, it reduces spontaneous differentiation with limited time and effort.
Non-neural ectoderm and pre-otic induction (steps 8-27). To start differentiation, hPS cells are dissociated and distributed, 5,000 cells per well, onto 96-well V-bottom plates. For this initial aggregation step we use E8 medium containing Y-27632, a potent ROCK signaling inhibitor. ROCK signaling inhibition has been shown to limit the amount of dissociation-induced apoptosis in hPS cells. Additionally, we have found that aggregation in E8 medium helps with cell survival and leads to more uniform cell aggregates, which impacts the reproducibility of the protocol. SB treatment inhibits TGFB to induce ectoderm development. Endogenous BMP signaling generates non-neural rather than neural ectoderm. FGF-2 and LDN treatment induces pre-placodal development. By day 8 the outer epithelium begins to express PAX8, indicating an oticepibranchial placode (OEPD)-like character. CHIR treatment on day 8 induces small patches of PAX2+ cells, indicating the earliest signs of otic placode development by day 12.
Otic prosensory vesicle and inner ear organoid formation (steps 28-43). A low concentration of extracellular matrix proteins (e.g., Matrigel™) does not seem to be supportive of otic vesicle formation. To encourage the otic placode-like patches to evaginate and pinch off from the epithelium as an otic vesicle, we embed day 12 aggregates in Matrigel. The Matrigel-embedded aggregates are cured onto the surface of bacterial dishes and bathed in a serum-free medium containing N2 and B27 supplement previously shown to support tissue self-organization (hereafter, Organoid Medium). This supportive environment, combined with continued exposure to CHIR, causes numerous vesicles to bud-off of the epithelium between days 12-18. Otic vesicle formation was observed in >95% of the aggregates (>100 aggregates) across four independent experiments. Additionally, between days 12-18, neuroblasts delaminate from other parts of the epithelium and differentiate into sensory neurons. It is currently unclear whether these sensory neurons are epibranchial neurons such as those of cranial nerves VII, IX, and X, or inner ear neurons such as the vestibular or spiral ganglion neurons. Formation of a mesenchyme containing chondrocyte progenitor cells was also observed. It was unclear, however, whether the chondrocyte progenitor cells arose from ectodermal epithelium or another population of mesodermal cells.
On day 18, the Matrigel®-embedded aggregates were removed from the stationary culture dish and pipetted into spinner flasks containing Organoid Medium devoid of any added growth factors or small molecules. After a total of 22 days, 10-30 vesicles were observed in each aggregate using phase contrast imaging. These vesicles expressed PAX2, PAX8, SOX2, and JAG1 protein indicating an otic cell fate. The vesicles appeared to grow slowly between days 22-35, and it became difficult to observe the vesicles using phase contrast imaging during this period due to the growing density of the mesenchymal cell mass in which they are embedded. By days 35-40, the vesicles were generally more apparent in the aggregate interior. The vesicles typically exhibited convoluted, multi-chambered morphologies, in contrast to the simple spherical and ovoid shaped otic vesicles. By day 45, vesicles have developed MYO7A+ hair cell-like cells and were identified as inner ear organoids. Between days 60-80, we observed MYO7A+ hair cells with F-actin-rich and Espin+ hair bundles, indicating a definitive hair cell identity.
Materials and Reagents
hPSC culture: Human PSCs (WA25 hESCs, passage 22-50; mND2-0 iPSCs, passage 28-46) were cultured in Essential 8 (E8) Medium or Essential 8 Flex Medium (E8f) (Invitrogen) supplemented with 100 μg/ml Normocin (Invivogen) on recombinant human Vitronectin-N (Invitrogen)-coated 6-well plates according to an established protocol12,13. At 80% confluency or every 4-5 days, the cells were passaged at a split ratio of 1:10-1:20 using an EDTA solution. Both cell lines were acquired from the WiCell Research Institute and arrived with a statement of verification and authenticity. Additional validation and testing information can be found on the cell line webpages, available at wicell.org/home/stem-cell-lines/catalog-of-stem-cell-lines/wa25.cmsx and wicell.org/home/stem-cell-lines/catalog-of-stem-cell-lines/mirjt7i-mnd2-0.cmsx on the World Wide Web. Cell lines were determined to be mycoplasma contamination-free using the MycoAlert Mycoplasma Detection Kit (Lonza).
Other reagents used in this exemplary protocol are set forth in Table 6.
Culture Medium and Stock Solutions
Human recombinant BMP7 stock solution (100 ng/μL): In the biosafety cabinet, add 100 μL of sterile 4 mM HCl to 10 μg of BMP7; vortex the solution and spin down in a tabletop centrifuge. Store BMP4 solution in 5 μL aliquots at −20° C. for 6 months or at −80° C. for 1 year.
Human recombinant FGF-2 stock solution (200 ng/μL): In the biosafety cabinet, add 250 μL of sterile PBS or 5 mM Tris (pH 7.6) to 50 μg of FGF-2; vortex the solution and spin down in a tabletop centrifuge. Store FGF-2 solution in 6 μL aliquots at −20° C. for 6 months or at −80° C. for 1 year.
Human transferrin stock solution (20 mg/ml): In the biosafety cabinet, dissolve 100 mg of recombinant human transferrin in 5 ml of IMDM. To fully dissolve, vortex the tube and place it on a rotating shaker for 5-10 min at room temperature (RT). Store the transferrin solution in 150 μl aliquots at −20° C. for 6 months or at −80° C. for 1 year.
EDTA Solution (for passaging hES cells): In the biosafety cabinet, mix 50 μl of 0.5 M EDTA into 50 ml DPBS. Filter sterilize the solution. EDTA solution can be stored at RT for 6 months.
Chemically Defined Medium (CDM): To prepare 200 mL CDM, measure out 1 g BSA in a 250 mL bottle. Dissolve the BSA in 100 mL F-12 Nutrient Mixture +GlutaMAX, 100 mL IMDM +GlutaMAX, 2 mL chemically-defined lipid concentrate, 140 μL Insulin, 150 μL Transferrin, and 8 μL 1-thioglycerol. Sterile filter using a low-protein binding filter. CDM should be used for up to 2 weeks and stored at 4° C. Add Normocin to the media just before use at a dilution of 2 μl per 1 mL of CDM. See Table 1 for a quick reference recipe.
Differentiation CDM: In a 50 mL conical tube, add 450 μL of ice cold Geltrex to 34.5 mL of ice cold CDM (1.25% final concentration). Vortex the tube well to fully dissolve the Geltrex. Place 30 mL of this solution in a new 50 mL conical tube. Add 0.6 μL of FGF-2 (4 ng/mL final concentration) and 30 μL of SB-431542 (10 μM final concentration). Vortex the tube well to mix. Differentiation CDM should be made fresh on day 0 of differentiation. Use the remaining 5 mL of CDM +Geltrex to wash the aggregates before plating.
Organoid Maturation Medium (OMM): To prepare 50 mL OMM, combine 24.5 mL Advanced DMEM/F12, 24.5 mL Neurobasal Medium, 500 μL B-27 Supplement without vitamin A, 500 μL GlutaMAX, 250 μL N2-supplement, and 100 μL Normocin in a sterile 50 mL conical tube. OMM can be used for up to 2 weeks if stored at 4° C. See Table 3 for a quick reference recipe.
Procedures
hES cell maintenance and passaging:
1. In the biosafety cabinet, dilute 60 μL of Vitronectin solution in 6 mL of DPBS. Add 1 mL of diluted vitronectin to each well of a 6-well culture plate. Incubate at RT for at least 1 hr and in the mean time proceed to step 2.
2. Equilibrate at least 20 mL of E8 Medium containing Normocin to RT.
3. To begin dissociation of the 70-80% confluent hES cells, aspirate the spent E8 Medium from one well and wash twice with DPBS.
4. Add 1 mL of EDTA solution and incubate in a 37° C. incubator for 4-8 min. Under a microscope, confirm that holes have formed in the center of the colonies.
5. During the EDTA incubation, remove the vitronectin solution from the 6-well plate and quickly add 1.5 mL of E8 Medium to each well before the surface dries.
6. Collect the dissociated cells into 6 mL of E8 Medium. CRITICAL You may need to vigorously triturate the medium to remove the cell clusters from the plate. Do not over pipet the cells, as this will cause apoptosis. Care should be taken to not introduce air bubbles into the medium.
7. Plate the cells on the prepared 6-well plate (from step 5). Select plating density based on when you next wish to split the cells. We typically add 500 mL (passage in 2-3 days) or 250 μL (passage in 4-5 days) of cell suspension to each well. Incubate cells at 37° C. in 5.0% CO2 until ready for passage or use in an experiment.
hES cell differentiation (day -2 to day 0): aggregation:
8. In the biosafety cabinet, prepare conical tubes containing 22 mL and 10 mL of E8 Medium with Normocin. Add 44 μL of Y-27632 to the 22 mL tube (20 μM final concentration; hereafter, E8-Y20) and 10 μL of Y-27632 to the 10 mL tube (10 μM final concentration; hereafter, E8-Y10).
9. When cells are 70-80% confluent, aspirate the E8 Medium from one well and wash three times with DPBS at RT.
10. Add 350 μL of TrypLE and incubate at 37° C. for 2-4 min. Following incubation, shake the plate horizontally to break up the cells. Under a microscope, confirm that the cells have rounded and are detached from the surface of the plate.
11. Collect the dissociated cells into 5 mL of E8-Y10 Medium and transfer them into a 15 mL conical tube.
12. Break the cell clumps into single-cells by pipetting with a P1000 tip. Pellet the cells, by centrifugation at 200 g for 5 minutes.
13. Completely remove the supernatant and resuspend the cell pellet in 1 mL of E8-Y10 Medium.
14. Forcefully pipet 1 mL of E8-Y10 Medium through a cell-strainer-top test tube to prime the strainer. Pipet the 1 mL of hES cell suspension drop-wise onto the cell strainer. Next, pipet 1 mL of E8-Y10 Medium drop-wise onto the cell strainer. There should be 3 mL in the test tube. This step is important for ensuring that the cells are completely dissociated into single cells.
15. Mix the cell suspension by pipetting with a P1000 tip and determine the concentration of cells using a hemocytometer or automated cell counter.
16. Dilute the appropriate volume of cell suspension in the 22 mL of E8-Y20 Medium to acquire a final concentration of 50,000 cells per mL (i.e., 1.1×106 total cells). For example, if the cell suspension contains 1×106 cells per mL, dilute 1.1 mL of cell suspension (1.1×106 divided by 1×106) in 20.9 mL of E8-Y20 Medium. Invert several times to mix.
17. Pour the cell suspension into a reservoir and aliquot 100 μl of cell suspension into each well of two 96-well V-bottom plates using a multichannel pipette.
18. Spin down the plates at 120 g for 5 min at RT.
19. Place the plates in a 37° C. incubator with 5.0% CO2 for 48 hrs. Add 50 μl of fresh E8 Medium (not containing Y-27632) to each well after 24 hrs.
Differentiation day 0: transfer to differentiation CDM:
20. Prepare 30 ml of Differentiation CDM containing Geltrex, FGF-2, and SB-431542. Allow the media to equilibrate to RT.
21. With the multichannel pipette set to 125 μl (i.e. 25 μl less than the volume of each well), carefully the aggregates from each well of the 96-well plate from step 18. Deposit the aggregates in a bacterial dish and then transfer them to a 2-ml tube.
22. Wash the aggregates at least 3 times with CDM to completely remove traces of E8 Medium.
23. Resuspend the aggregates in differentiation CDM and transfer them to a new bacterial dish.
24. Using a P200 pipette, individually transfer each aggregate to each well of two 96-well U-bottom plates in 100 μl of media. It may be difficult to see the aggregates at this stage. We typically place the bacterial dish on a non-reflective white surface (e.g., a Kimwipe) to enhance the contrast of the aggregates.
25. Return plates to the incubator for 4 days. Observe the morphology of the aggregates daily.
Differentiation day 4: addition of FGF-2 and LDN-193189 (FGF/LDN):
26. In a 15-ml conical tube, add FGF-2 and LDN-193189 to the CDM at a 5× concentration. For example, we add 6.25 μl of 200 ng/μl FGF-2 and 0.5 μL of 10 mM LDN-193189 to 5 ml of CDM.
27. Add 25 μl of CDM containing FGF/LDN to each well of the plate from step 24. Each well now contains 125 μl of medium with a final concentration of 50 ng/ml FGF-2 and 200 nM LDN-193189. Incubate cells for a further 4 days.
28. In a 15-ml conical tube, add CHIR99021 to the CDM at a 6× concentration. For example, we add 9μl of 10 mM CHIR99021 to 5 ml of CDM.
29. Add 25 μl of CDM containing CHIR to each well of the plate from step 26. Each well now contains 125 μl of medium with a final concentration of 3 μM CHIR. Incubate cells for a further 4 days.
Differentiation day 12: transition to static ECM culture:
30. About 2 hrs prior to performing the following steps, remove a 1-ml aliquot of Geltrex from the freezer and allow it to thaw completely on ice or in the refrigerator.
31. Prepare 50 ml of organoid medium in a 50-ml conical tube.
32. Using a cut P1000 pipette tip, transfer the aggregates from each well of the plate in step 28 into a 2-ml tube.
33. Allow the aggregates to settle at the bottom of the tube and then carefully aspirate the media.
34. Wash the aggregates with 1-2 ml of RT organoid medium at least 3 times. Remove as much of the medium as possible following the final wash.
35. Resuspend the aggregates in ice-cold Geltrex. Set the pipette to 20 μl and individually transfer the aggregates to a 100 mm bacterial dish. We typically add 20-30 droplets to each plate. Gentle shaking the plate in different directions helps to flatten and adhere the droplets to the surface of the plate. Geltrex will begin to polymerize after 10-15 minutes at RT. It is recommended to keep a small container of ice in biosafety cabinet where the aggregate/Geltrex mixture can be placed between pipetting steps.
36. Incubate the plates without medium for 30 minutes at 37° C.
37. Add 10-12 ml of organoid medium containing CHIR. Add the orgnaoid medium slowly as to not detach the droplets from the plate. It is fine if some droplets may detach.
38. Incubate cells for a further 6 days. Perform a half media change after 3 days.
Differentiation day 18: transition to spinner flask:
39. Using a wide-mouth P1000 tip, scrape-off and pipette-up each aggregate from the surface of the bacterial dish. Transfer the aggregates to a 2-ml tube.
40. Wash the aggregates 3 times with organoid medium.
41. Pour 50-75 ml of organoid medium into a 125-ml spinner flask.
42. Add the aggregates to the spinner flask. Confirm that the side ports are opened by a ¼ turn and place the spinner flask in the incubator on the stirrer plate. Set the stirrer controller at 60-65 rpm.
43. Incubate cells for a further 22-42 days. Completely change the medium every week. For longer experiments, aggregates can be maintained in the spinner flask indefinitely. To monitor development, we periodically transfer the aggregates to a bacterial dish using wide-mouth P1000 and image using an inverted microscope.
Timing:
Steps 1-7, Maintenance and passaging hES cells: 30 min
Steps 8-19, hES cell differentiation: Aggregation: 40 min
Steps 20-25, Differentiation day 0: Transfer to Differentiation CDM: 1 hr
Steps 26-27, Differentiation day 4: Addition of FGF-2 and LDN-193189: 20 min
Steps 28-29, Differentiation day 8: Addition of CHIR99021: 20 min
Steps 30-38, Differentiation day 12: Transition to static ECM culture: 45 min
Steps 39-43, Differentiation day 18: Transition to bioreactor: 30 min
Steps 1-43, Total time to generate inner ear organoids: 45-60 days to >1 yr
Claims
1. A method of obtaining human pre-otic epithelial cells, comprising the steps of:
- (a) culturing human pluripotent stem cell aggregates in a culture medium comprising a Bone Morphogenetic Protein (BMP) and an inhibitor of Transforming Growth Factor Beta (TGFβ) signaling for about eight to about ten days;
- (b) further culturing the cultured aggregates of (a) in the presence of a Fibroblast Growth Factor (FGF) and an inhibitor of BMP signaling for about 4 days; and
- (b) contacting the further cultured aggregates of (b) to a Wnt agonist for about 4 days;
- whereby cells within the contacted aggregates differentiate into pre-otic epithelial cells.
2. The method of claim 1, wherein the FGF is FGF-2.
3. The method of claim 1, wherein the BMP is selected from the group consisting of BMP2, BMP4, and BMP7.
4. The method of claim 1, wherein the inhibitor of BMP signaling is LDN-193189.
5. The method of claim 1, wherein the inhibitor of TGFβ1-mediated signaling is selected from the group consisting of SB431542 and A-83-01.
6. The method of claim 1, wherein the Wnt agonist is an inhibitor of GSK3.
7. The method of claim 6, wherein the inhibitor of GSK3 is selected from the group consisting of CHIR99021, lithium chloride (LiCl), and 6-bromoindirubin-3′-oxime (BIO).
8. A method of obtaining a three-dimensional composition comprising human inner ear sensory tissue, the method comprising the steps of
- (a) embedding human pre-otic epithelial cells obtained according to the method of claim 1 in a semi-solid culture medium comprising extracellular matrix protein;
- (b) culturing the embedded pre-otic epithelial cells in the presence of a Wnt agonist for about 40 to about 60 days under conditions that promote self-assembly of embedded pre-otic epithelial cells into otic vesicles, whereby a three-dimensional composition comprising human inner ear sensory tissue is obtained.
9. The method of claim 8, wherein the Wnt agonist is an inhibitor of GSK3.
10. The method of claim 9, wherein the inhibitor of GSK3 is selected from the group consisting of CHIR99021, lithium chloride (LiCl), and 6-bromoindirubin-3′-oxime (BIO).
11. The method of claim 8, wherein the extracellular matrix is a basement membrane extract (BME).
12. The method of claim 8, wherein the three-dimensional composition comprises one or more mechanosensory cells.
13. The method of claim 8, wherein the three-dimensional composition comprises one or more sensory neuron cells.
14. The method of claim 8, wherein the three-dimensional composition comprises one or more sensory neuron cells that form synaptic connections with mechanosensory cells.
Type: Application
Filed: Oct 21, 2016
Publication Date: Mar 28, 2019
Applicant: Indiana University Research and Technology Corporation (Indianapolis, IN)
Inventors: Karl R. Koehler (Indianapolis, IN), Eri Hashino (Indianapolis, IN)
Application Number: 15/769,254
